FDA reform agreement hampered by lack of initial patient involvement, FDA's Schultz argues at FDLI.
Executive Summary
FDA REFORM MUST FOCUS ON BOTH PATIENT AND INDUSTRY CONCERNS, FDA DEPUTY Commissioner for Policy William Schultz declared Sept. 5 at a Food & Drug Law Institute meeting in Washington, D.C. Schultz told FDLI that creating comprehensive bipartisan support for FDA reform has been difficult because current legislation is based on industry proposals, which do not address the concerns of patient and consumer groups.